Isabelle Lecomte
Overview
Explore the profile of Isabelle Lecomte including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
177
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Plazzi G, Mayer G, Bodenschatz R, Bonanni E, Cicolin A, Della Marca G, et al.
Sleep Med
. 2025 Feb;
129:20-30.
PMID: 39978240
Background: Narcolepsy is a chronic sleep disorder characterized mainly by excessive daytime sleepiness (EDS) and cataplexy in the case of narcolepsy type 1 (NT1). Pitolisant is a histamine 3 receptor...
2.
Pepin J, Attali V, Causse C, Verbraecken J, Hedner J, Lecomte I, et al.
Chest
. 2023 Nov;
165(3):692-703.
PMID: 37979718
Background: In people with OSA, excessive daytime sleepiness is a prominent symptom and can persist despite adherence to CPAP, the first-line therapy for OSA. Pitolisant was effective in reducing daytime...
3.
Dauvilliers Y, Lecendreux M, Lammers G, Franco P, Poluektov M, Causse C, et al.
Lancet Neurol
. 2023 Mar;
22(4):303-311.
PMID: 36931805
Background: Narcolepsy is a life-long disorder characterised by excessive daytime sleepiness and cataplexy, often arising in childhood or adolescence. Pitolisant, a selective histamine H3 receptor inverse agonist, has been approved...
4.
Mutti C, Brunetti V, Figorilli M, Liguori C, Pizza F, Proserpio P, et al.
Neurol Sci
. 2022 Jun;
43(9):5563-5574.
PMID: 35750949
Introduction: Narcolepsy is a chronic and rare hypersomnia of central origin characterized by excessive daytime sleepiness and a complex array of symptoms as well as by several medical comorbidities. With...
5.
Pepin J, Georgiev O, Tiholov R, Attali V, Verbraecken J, Buyse B, et al.
Chest
. 2020 Oct;
159(4):1598-1609.
PMID: 33121980
Background: Excessive daytime sleepiness (EDS) in individuals with OSA syndrome persisting despite good adherence to CPAP is a disabling condition. Pitolisant is a selective histamine H3-receptor antagonist with wake-promoting effects....
6.
Dauvilliers Y, Verbraecken J, Partinen M, Hedner J, Saaresranta T, Georgiev O, et al.
Am J Respir Crit Care Med
. 2020 Jan;
201(9):1135-1145.
PMID: 31917607
Excessive daytime sleepiness is a common disabling symptom in obstructive sleep apnea syndrome. To evaluate the efficacy and safety of pitolisant, a selective histamine H3 receptor antagonist with wake-promoting effects,...
7.
Dauvilliers Y, Arnulf I, Szakacs Z, Leu-Semenescu S, Lecomte I, Scart-Gres C, et al.
Sleep
. 2019 Sep;
42(11).
PMID: 31529094
Study Objectives: To asses the long-term safety and efficacy of pitolisant, an histamine H3-receptor antagonist, on narcolepsy. Methods: This open-label, single-arm, pragmatic study, recruited adult patients with narcolepsy and Epworth...
8.
Szakacs Z, Dauvilliers Y, Mikhaylov V, Poverennova I, Krylov S, Jankovic S, et al.
Lancet Neurol
. 2017 Jan;
16(3):200-207.
PMID: 28129985
Background: Histaminergic neurons are crucial to maintain wakefulness, but their role in cataplexy is unknown. We assessed the safety and efficacy of pitolisant, a histamine H3 receptor inverse agonist, for...
9.
Bachmeyer C, Bagur E, Lenglet T, Maier-Redelsperger M, Lecomte I
Am J Med
. 2012 Apr;
125(6):e5-6.
PMID: 22483060
No abstract available.
10.
Stojanovic K, Thioliere B, Garandeau E, Lecomte I, Bachmeyer C, Lionnet F
Br J Haematol
. 2011 Apr;
155(2):271-2.
PMID: 21488859
No abstract available.